{"$schema": "https://iptc.org/std/ninjs/ninjs-schema_3.2.json", "uri": "urn:newsml:wireva.mib.news:item:8ac60248-0f99-4e9f-ae13-2b12b0ba2634", "type": "text", "profile": "update", "version": "1", "versioncreated": "2026-10-01T11:04:58.644947Z", "firstcreated": "2026-10-01T11:01:23.999220Z", "pubstatus": "usable", "urgency": 5, "language": "en", "headline": "New Amylin-Based Weight-Loss Drugs Show Fewer Side Effects in Late-Stage Trials", "byline": "Blake Kendall", "located": "United States", "copyrightholder": "Haydamax OÜ", "copyrightnotice": "Wireva / Boldest Voice", "usageterms": "Monitoring item. Headline, short extract and the source link may be shown. Do not republish the full text.", "description_text": "Researchers at the European Association for the Study of Diabetes in Milan reported encouraging results for a new class of injectable weight-loss drugs called amylins, which appear to cause fewer gastrointestinal side effects than existing GLP-1 medications. Novo Nordisk's CagriSema helped patients lose 22.4% of body weight, while Eli Lilly's combination drug achieved 23% weight loss.", "altids": {"mosaic": "8ac60248-0f99-4e9f-ae13-2b12b0ba2634", "story": "26203f5b-8e71-4b1b-a9fe-fb912569f163", "slug": "new-amylin-based-weight-loss-drugs-show-fewer-side-effects-in-late-stage-trials"}, "subject": [{"name": "Society", "rel": "direct", "literal": "society", "code": "medtop:14000000", "scheme": "http://cv.iptc.org/newscodes/mediatopic/", "uri": "http://cv.iptc.org/newscodes/mediatopic/14000000"}], "place": [{"name": "United States", "literal": "us", "code": "US", "scheme": "http://cv.iptc.org/newscodes/countrycodes/"}], "person": [], "organisation": [], "genre": [{"name": "Updated story", "literal": "update"}], "service": [{"name": "Wireva", "literal": "wireva"}], "body_text": "Researchers at the European Association for the Study of Diabetes in Milan reported encouraging results for a new class of injectable weight-loss drugs called amylins, which appear to cause fewer gastrointestinal side effects than existing GLP-1 medications. Novo Nordisk's CagriS", "extra_body_note": "Extract only — see rights.class = link_only.", "associations": {"featuremedia": {"uri": "urn:newsml:wireva.mib.news:media:974d4425-96e7-4ef9-9405-c22d32c97294", "type": "picture", "version": "1", "pubstatus": "usable", "headline": "The Next Generation of Weight-Loss Drugs Is Almost Here", "description_text": "New Amylin-Based Weight-Loss Drugs Show Fewer Side Effects in Late-Stage Trials", "copyrightholder": "static.time.com", "copyrightnotice": "The Next Generation of Weight-Loss Drugs Is Almost Here", "usageterms": "Picture belongs to the source publication: address and terms are delivered, the file is not.", "altids": {"wireva": "974d4425-96e7-4ef9-9405-c22d32c97294"}, "extra": {"wireva:delivery_mode": "link_only", "wireva:rights": {"licence": "", "licence_url": "", "licence_raw": "RSS source", "licence_verified_at": "2026-10-01T11:04:58.661763Z", "attribution_required": true, "attribution_text": "The Next Generation of Weight-Loss Drugs Is Almost Here", "redistribution_allowed": false, "commercial_use_allowed": false, "modifications_allowed": false, "share_alike_required": false}, "wireva:provenance": {"creator": "", "source_name": "static.time.com", "source_url": "https://static.time.com/v3/assets/bltea6093859af6183b/bltb049fbfae9aa1db9/6abd79819e734422e707718d/GettyImages-2294172943.jpg?branch=production", "source_page_url": "https://static.time.com/v3/assets/bltea6093859af6183b/bltb049fbfae9aa1db9/6abd79819e734422e707718d/GettyImages-2294172943.jpg?branch=production", "our_page_url": "https://boldestvoice.com/society/new-amylin-based-weight-loss-drugs-show-fewer-side-effects-in-late-stage-trials/"}, "wireva:role": "lead"}, "renditions": {"source": {"href": "https://static.time.com/v3/assets/bltea6093859af6183b/bltb049fbfae9aa1db9/6abd79819e734422e707718d/GettyImages-2294172943.jpg?branch=production", "mimetype": "image/jpeg"}}}}, "extra": {"wireva:story": {"uri": "urn:newsml:wireva.mib.news:story:26203f5b-8e71-4b1b-a9fe-fb912569f163", "slug": "leading-ai-researchers-warn-of-extreme-risks-from-automated-ai-research-20260928", "status": "updated", "languages": ["en", "fr", "pl", "uk"], "item_count": 19, "is_breaking": false}, "wireva:rights": {"class": "link_only", "redistribution_allowed": false, "commercial_use_allowed": false, "modifications_allowed": true, "share_alike_required": false, "attribution_required": true, "attribution_text": "Wireva / Boldest Voice", "canonical_required": true, "canonical_url": "https://boldestvoice.com/society/new-amylin-based-weight-loss-drugs-show-fewer-side-effects-in-late-stage-trials/", "linkback_required": true, "licence": "", "licence_url": "", "licensor": "Haydamax OÜ", "valid_until": null, "excerpt_max_chars": 280, "decided_by_rule": "derivation_failed", "needs_review": true}, "wireva:provenance": {"production_method": "automated", "ai_stages": {"editing": true, "drafting": true, "headline": true, "discovery": true, "classification": true, "image_selection": true, "source_collection": true, "cross_source_comparison": true}, "model": "", "human_reviewed": false, "reviewed_by": "", "reviewed_at": null, "editorial_control": true, "editorial_responsibility": "Haydamax OÜ (Wireva)", "factchecked": false, "verification_status": "multi_source", "independent_confirmations": 2, "official_source_used": false, "used_press_release": false, "public_interest": true, "ai_disclosure_required": true, "ai_disclosure_text": "This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.", "independence_check": {"status": "failed", "score": 0.82, "checked_at": "2026-10-01T11:04:58.658785Z"}}, "wireva:publication": {"name": "Boldest Voice", "domain": "boldestvoice.com", "country": "US", "url": "https://boldestvoice.com/society/new-amylin-based-weight-loss-drugs-show-fewer-side-effects-in-late-stage-trials/"}, "wireva:links": {"self": "https://wireva.mib.news/api/v1/items/8ac60248-0f99-4e9f-ae13-2b12b0ba2634", "html": "https://wireva.mib.news/item/8ac60248-0f99-4e9f-ae13-2b12b0ba2634/new-amylin-based-weight-loss-drugs-show-fewer-side-effects-in-late-stage-trials/", "story": "https://wireva.mib.news/story/leading-ai-researchers-warn-of-extreme-risks-from-automated-ai-research-20260928/"}, "wireva:metrics": {"word_count": 665, "char_count": 4242, "reading_time_seconds": 303}}}